Proactive Investors - Run By Investors For Investors

Futura Medical Plc progresses condom and pain relief products

Health group expects to have more of a commercial focus in 2016
Futura Medical Plc progresses condom and pain relief products
Futura said 2015 was a period of intense clinical activity

Futura Medical Plc (LON:FUM) forecast lower research & development spending this year as it reported progress with its pain relief and sexual health products.

Futura said 2015 was a period of intense clinical activity during which it made "significant advances" in programmes in erectile dysfunction and pain relief.

It said it expected R&D outlay to be significantly lower this year, when it would have more of a focus on commercial product development.

In June, the group began a pivotal efficacy study for its MED2002 treatment for erectile dysfunction, which is expected to produce headline results by the end of the first half.

Futura has achieved an extended shelf life for its CSD500 condom, which maintains a firmer erection, maximises penile size and gives women a longer-lasting sexual experience.

It has applied to get a modified manufacturing process for the condom approved in Europe and expects to receive consent in the middle of this year.

It also reported major progress in its pain relief portfolio during 2015, specifically in achieving statistically significant results in a study of two gels, TPR100 and TIB200.

"The US also represents a very significant opportunity for TPR100 and we are preparing for a meeting with the US Food and Drug Administration in the near future to clarify the remaining requirements for US regulatory approval," the group said in its results for the year to the end of December.

Net losses widened to £5.08mln from £3mln in 2014, reflecting two clinical studies undertaken in 2015.

Chief executive James Barder said: "We have made important progress with the shelf life extension of our novel condom CSD500 and we look forward to the start of licensee launches in 2016 and beyond.

"Futura has also made significant advances in its clinical programmes in erectile dysfunction and pain relief. In 2016 we expect to build on that progress and look forward to providing further updates."
















View full FUM profile View Profile

Futura Medical PLC Timeline

Related Articles

Zelda's Stewart Washer at Proactive's CEO Sessions
November 17 2017
Stewart Washer at Proactive's CEO Sessions this week.
Regeneus: Access latest PPT from Proactive's CEO Sessions
June 18 2017
John Martin discussed regenerative medicine with investors.
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use